CytoDyn leadership team to attend ESMO Breast Cancer meeting

CytoDyn (CYDY) announced that the Company will be presenting a poster at the upcoming European Society for Medical Oncology’s Breast Cancer meeting, following its promising survival observations among patients with metastatic triple-negative breast cancer treated with leronlimab. The conference will take place on May 14-17, 2025, in Munich, Germany, and CytoDyn’s presentation is scheduled for May 15, 2025. As announced in February 2025, a review of patients treated with leronlimab during CytoDyn’s prior clinical trials in oncology revealed observed survival rates at 12, 24, and 36 months that compare favorably to expected outcomes with currently approved therapies. The Company has also now confirmed survival outcomes in a group of patients with mTNBC and four prior lines of treatment who are alive more than 48 months after receiving leronlimab. This includes four patients who currently identify as having no evidence of ongoing disease and a fifth patient who is alive with stable disease. CytoDyn has already initiated a follow-up protocol to continue to monitor these surviving patients into the future. “We look forward to sharing details on the progress we have made advancing our clinical development pipeline for leronlimab in oncology,” said Dr. Lalezari. “We are also excited to share information about the apparent mechanism of action in long-term surviving patients that we see as a potentially paradigm-shifting development in solid tumor oncology.”